YAVNE, Israel, June 2, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management participate at the Jefferies 2014 Global Healthcare Conference taking place from June 2-5, 2014 in New York City. Gal Cohen, President and Chief Executive Officer, and Sharon Malka, Chief Financial Officer, will deliver MediWound's corporate presentation on Thursday, June 5th at 11:30 a.m. Eastern
time.
The Company's presentation will be webcast live on the internet and can be accessed by visiting the Investor Relations section of the Company's website at www.mediwound.com. A replay of the webcast will be archived on the MediWound website for 90 days following the presentation.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
CONTACT: Sharon Malka
CFO
MediwoundSharon@mediwound.co.il
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com
Source:
MediWound
News Provided by Acquire Media